Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of BL-B01D1 monotherapy, SI-B003 monotherapy, and BL-B01D1 + SI-B003 in recurrent or metastatic gynecologic malignancies including cervical cancer
CTR20232433Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Nov 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab brengitecan, SI-B003 in Cervical Cancer (CC), gynecological cancer, sponsored by Biokin Pharmaceutical. Started Nov 2023; status: active.
02
Drugs
izalontamab brengitecanSI-B003
03
Conditions
Cervical Cancer (CC)gynecological cancer
Beyond the preview
Go deeper on CTR20232433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232433.